Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The antifibrotic agents, namely pirfenidone and nintedanib have been found to be effective in
the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib has also been found to be
effective in treating systemic sclerosis-related interstitial lung disease (ILD) and non-IPF
progressive fibrosing ILDs. Pirfenidone has also been found beneficial unclassifiable ILDs.
Whether these drugs would be effective in treating post-COVID lung fibrosis also is unknown.
As the final pathway of lung fibrosis appears to be common among different diffuse
parenchymal lung diseases (DPLDs), it is hoped that these antifibrotic agents might be
helpful in post-COVID fibrosis. There are no randomized studies that have assessed the role
of pirfenidone or nintedanib in post COVID fibrosis. In the current study, we aim to assess
the efficacy and safety of pirfenidone and compare it with nintedanib in the treatment of
post-COVID lung fibrosis.
Phase:
Phase 4
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research